JAK抑制剂Baricitinib-话题@MedSci

#JAK抑制剂Baricitinib#

6篇内容 | 1506人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2244365, encodeId=a25422443652e, content=<a href='/topic/show?id=04cb1e21583' target=_blank style='color:#2F92EE;'>#TCS#</a> <a href='/topic/show?id=c46810238d2' target=_blank style='color:#2F92EE;'>#JAK抑制剂Baricitinib#</a> <a href='/topic/show?id=313311242e4b' target=_blank style='color:#2F92EE;'>#中重度特应性皮炎#</a>, objectTitle=Front Allergy：Baricitinib单药治疗和是否外用TCS治疗中重度特应性皮炎对比研究, objectType=article, longId=856242, objectId=1f3985624244, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240612/1718156655948_92910.jpg, objectUrl=/article/show_article.do?id=1f3985624244, replyNumber=0, likeNumber=32, createdTime=2024-12-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=1f3985624244, moduleTitle=Front Allergy：Baricitinib单药治疗和是否外用TCS治疗中重度特应性皮炎对比研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f3985624244)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1480772, encodeId=39b81480e728e, content=<a href='/topic/show?id=c46810238d2' target=_blank style='color:#2F92EE;'>#JAK抑制剂Baricitinib#</a>, objectTitle=Science Advances：JAK抑制剂Baricitinib将新冠COVID-19患者死亡率降低71%, objectType=article, longId=203491, objectId=bf832034914b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf832034914b, replyNumber=0, likeNumber=95, createdTime=2020-11-18, rootId=0, userName=ms2694732865965676, userId=320b7680428, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf832034914b, moduleTitle=Science Advances：JAK抑制剂Baricitinib将新冠COVID-19患者死亡率降低71%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf832034914b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480771, encodeId=683c1480e714b, content=<a href='/topic/show?id=c46810238d2' target=_blank style='color:#2F92EE;'>#JAK抑制剂Baricitinib#</a>, objectTitle=EADV 2020：JAK抑制剂Baricitinib治疗湿疹，展现长期疗效和安全性, objectType=article, longId=202999, objectId=8918202999cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8918202999cd, replyNumber=0, likeNumber=90, createdTime=2020-11-08, rootId=0, userName=ms2694732865965676, userId=320b7680428, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8918202999cd, moduleTitle=EADV 2020：JAK抑制剂Baricitinib治疗湿疹，展现长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8918202999cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480770, encodeId=14871480e709b, content=<a href='/topic/show?id=c46810238d2' target=_blank style='color:#2F92EE;'>#JAK抑制剂Baricitinib#</a>, objectTitle=关节炎药物JAK抑制剂Baricitinib治疗斑秃：患者获得显著改善, objectType=article, longId=202774, objectId=0f2d202e740f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f2d202e740f, replyNumber=0, likeNumber=70, createdTime=2020-11-03, rootId=0, userName=ms2694732865965676, userId=320b7680428, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f2d202e740f, moduleTitle=关节炎药物JAK抑制剂Baricitinib治疗斑秃：患者获得显著改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f2d202e740f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480769, encodeId=31d91480e6912, content=<a href='/topic/show?id=c46810238d2' target=_blank style='color:#2F92EE;'>#JAK抑制剂Baricitinib#</a>, objectTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, objectType=article, longId=190457, objectId=fbcc19045e07, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbcc19045e07, replyNumber=0, likeNumber=86, createdTime=2020-03-21, rootId=0, userName=ms2694732865965676, userId=320b7680428, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbcc19045e07, moduleTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbcc19045e07)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480768, encodeId=9d6e1480e6848, content=<a href='/topic/show?id=c46810238d2' target=_blank style='color:#2F92EE;'>#JAK抑制剂Baricitinib#</a>, objectTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, objectType=article, longId=187166, objectId=2f3218e16658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f3218e16658, replyNumber=0, likeNumber=105, createdTime=2020-02-03, rootId=0, userName=ms2694732865965676, userId=320b7680428, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f3218e16658, moduleTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f3218e16658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480767, encodeId=034e1480e673e, content=<a href='/topic/show?id=c46810238d2' target=_blank style='color:#2F92EE;'>#JAK抑制剂Baricitinib#</a>, objectTitle=JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症, objectType=article, longId=186909, objectId=12e1186909d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12e1186909d9, replyNumber=0, likeNumber=79, createdTime=2020-01-30, rootId=0, userName=ms2694732865965676, userId=320b7680428, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12e1186909d9, moduleTitle=JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12e1186909d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JAK抑制剂Baricitinib

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#TCS# #JAK抑制剂Baricitinib# #中重度特应性皮炎#

Front Allergy：Baricitinib单药治疗和是否外用TCS治疗中重度特应性皮炎对比研究

2024-12-22发表于陕西省

ms2694732865965676 (审核中...)

前往app查看评论内容

#JAK抑制剂Baricitinib#

Science Advances：JAK抑制剂Baricitinib将新冠COVID-19患者死亡率降低71%

2020-11-18

ms2694732865965676 (审核中...)

前往app查看评论内容

#JAK抑制剂Baricitinib#

EADV 2020：JAK抑制剂Baricitinib治疗湿疹，展现长期疗效和安全性

2020-11-08

ms2694732865965676 (审核中...)

前往app查看评论内容

#JAK抑制剂Baricitinib#

关节炎药物JAK抑制剂Baricitinib治疗斑秃：患者获得显著改善

2020-11-03

ms2694732865965676 (审核中...)

前往app查看评论内容

#JAK抑制剂Baricitinib#

礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号

2020-03-21

ms2694732865965676 (审核中...)

前往app查看评论内容

#JAK抑制剂Baricitinib#

礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果

2020-02-03

ms2694732865965676 (审核中...)

前往app查看评论内容

#JAK抑制剂Baricitinib#

JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症

2020-01-30

科室
- - 订阅+
  - 更多科室
工具
服务